Cancer clinical trials in the region Pays de la Loire

317 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account
and find trials relevant to your profile

Phase 2 Stomach and esophageal cancer #NCT06846346 #2025-520694-39-00

Évaluation de l'IVONESCIMAB en association avec une chimiothérapie dans l'adénocarcinome gastrique/gastro-œsophagien avancé ou métastatique - Cohorte 1

Stomach Oesogastric junction Adenocarcinoma Locally Advanced Metastatic None Systemic Treatment-Naive CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)

Claudin 18.2 HER2 MSI/dMMR

Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain)

Phase 2 Stomach and esophageal cancer #NCT06846346 #2025-520694-39-00

Évaluation de l'IVONESCIMAB en association avec une chimiothérapie dans l'adénocarcinome gastrique/gastro-œsophagien avancé ou métastatique - Cohorte 2

Stomach Oesogastric junction Adenocarcinoma Locally Advanced Metastatic Claudin 18.2 HER2 1 CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)

MSI/dMMR Systemic Treatment-Naive

Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain)

Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT04678362 #2024-516182-37-01

[TALASUR] TALazoparib et avelumab en traitement d'entretien du carcinome urothélial métastatique ou localement avancé sensible au platine

Invasive bladder cancer Upper excretory tract cancer Urethral cancer Urothelial carcinoma Other Locally Advanced Metastatic None Chemotherapy

Immunotherapy Targeted therapy

Institut de Cancérologie de l'Ouest - Site d'Angers (Angers ), Institut de Cancérologie de l'Ouest - Site d'Angers (Angers )

Centre François Baclesse

Phase 2 Lung cancer #NCT05967689 #2023-503865-48-00

[RÉZILIENT2] Etude sur le ZIPALERTINIB chez des patients atteints d'un cancer du poumon non à petites cellules avancé avec insertions de l'exon 20 de l'EGFR ou autre mutation peu courante - Sous-étude d'optimisation de dose

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR 1 Chemotherapy

Systemic Treatment-Naive Systemic Treatment-Naive

Centre Hospitalier Universitaire de Nantes (Nantes), Centre Hospitalier Universitaire Laennec (Saint-Herblain)

Taiho Oncology

Phase 2 Lung cancer #NCT05967689 #2023-503865-48-00

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR 1 Chemotherapy Targeted therapy

Systemic Treatment-Naive Systemic Treatment-Naive

Centre Hospitalier Universitaire de Nantes (Nantes), Centre Hospitalier Universitaire Laennec (Saint-Herblain)

Taiho Oncology

Phase 2 Lung cancer #NCT05967689 #2023-503865-48-00

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR 1

Systemic Treatment-Naive Systemic Treatment-Naive

Centre Hospitalier Universitaire de Nantes (Nantes), Centre Hospitalier Universitaire Laennec (Saint-Herblain)

Taiho Oncology

Phase 2 Stomach and esophageal cancer #NCT06172478 #2023-507641-29-00

[HERTHENA-PanTumor01] Etude sur HER3-DXd chez des sujets atteints de tumeurs solides localement avancées ou métastatiques

Carcinome épidermoïde de l’œsophage

Esophagus Squamous cell carcinoma Locally Advanced Metastatic 2 Chemotherapy

Systemic Treatment-Naive

Centre Hospitalier Universitaire de Nantes (Nantes)

Daiichi Sankyo

Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT06172478 #2023-507641-29-00

[HERTHENA-PanTumor01] Etude sur HER3-DXd chez des sujets atteints de tumeurs solides localement avancées ou métastatiques

Carcinome urothélial

Invasive bladder cancer Non-invasive bladder cancer Upper excretory tract cancer Urethral cancer Locally Advanced Metastatic 1 2 3 or more Immunotherapy Chemotherapy

Systemic Treatment-Naive

Centre Hospitalier Universitaire de Nantes (Nantes)

Daiichi Sankyo

Phase 2 Breast cancer #NCT06172478 #2023-507641-29-00

[HERTHENA-PanTumor01] Etude sur HER3-DXd chez des sujets atteints de tumeurs solides localement avancées ou métastatiques

Cancer du sein

HER2 Negative HR Positive Locally Advanced Metastatic 1 Chemotherapy Targeted therapy Hormone therapy

ALK BRAF EGFR HER2 KRAS G12C MET NTRK-1/2/3 RET ROS-1 Systemic Treatment-Naive

Centre Hospitalier Universitaire de Nantes (Nantes)

Daiichi Sankyo

Phase 2 Pancreas cancer #NCT06172478 #2023-507641-29-00

[HERTHENA-PanTumor01] Etude sur HER3-DXd chez des sujets atteints de tumeurs solides localement avancées ou métastatiques

Adénocarcinome du pancréas

Adenocarcinoma Locally Advanced Metastatic 1

Systemic Treatment-Naive

Centre Hospitalier Universitaire de Nantes (Nantes)

Daiichi Sankyo